Table 5.

Risks of Malignancy Events by Treatment Arm and Year of Follow-Up

Endpoints	Years of Follow-Up	Simvastatin Monotherapy		Simvastatin/Ezetimibe		HR (95% CI)	p Value
		N	n (%)	N	n (%)
Primary malignancy endpoint
	≤1	8,848	129	8,847	133	1.04 (0.81–1.32)	0.77
	>1 and ≤2	8,199	125	8,136	131	1.05 (0.82–1.34)	0.68
	>2 and ≤3	7,798	117	7,776	130	1.11 (0.87–1.43)	0.40
	>3 and ≤4	7,468	95	7,454	109	1.15 (0.87–1.51)	0.33
	>4 and ≤5	6,988	95	6,971	96	1.01 (0.76–1.35)	0.92
	>5 and ≤6	5,234	80	5,191	70	0.88 (0.64–1.22)	0.44
	>6 and ≤7	4,168	57	4,132	44	0.78 (0.52–1.15)	0.21
Deaths due to malignancy
	≤1	8,855	20	8,853	28	1.40 (0.79–2.49)	0.25
	>1 and ≤2	8,590	44	8,557	36	0.82 (0.53–1.27)	0.37
	>2 and ≤3	8,373	55	8,378	43	0.78 (0.52–1.16)	0.22
	>3 and ≤4	8,144	42	8,168	41	0.97 (0.63–1.49)	0.89
	>4 and ≤5	7,715	36	7,755	49	1.36 (0.89–2.09)	0.16
	>5 and ≤6	5,921	34	5,891	44	1.30 (0.83–2.04)	0.25
	>6 and ≤7	4,802	25	4,757	23	0.93 (0.53–1.64)	0.80

Abbreviations as in Table 2 and3.